Floatz logo

Sabizabulin

Metastatic Castration-resistant Prostate Cancer

Veru Inc.Phase 3Dormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
65/ 100

Competitive context

252 Active assets in the Metastatic Castration-resistant Prostate Cancer cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Mayo Clinic
Phase 4BBB
Fluciclovine
VA Greater Los Angeles Healthcare System
Phase 4BBB
LEUPROLIDE
Mayo Clinic
Phase 4BBB
Abiraterone Acetate
Mayo Clinic
Phase 4BB
PREDNISONE TABLETS
Mayo Clinic
Phase 4BB

View all 50 →

Same molecule, other indications

Sabizabulin is also rated in:

breast cancerDormant
D
Indicative ·
29 / 100
View asset →
triple-negative breast carcinomaDormant
D
Indicative ·
29 / 100
View asset →
Metastatic Castration Resistant Prostate CancerDormant
D
Indicative ·
26 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →